Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine, a ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...

House: Johnson & Johnson has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA) for ...

Immunovant said on Wednesday its experimental treatment for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer ...

The good news, experts said, is that most Americans don't need a booster -- especially those who received two doses of the ...

Wildfire smoke exposure acutely increased IL-13 expression in NK cells and was negatively associated with COVID-19 vaccine immunity.

Spring House, Pennsylvania Wednesday, March 19, 2025, 14:00 Hrs [IST] ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...

Spring is a busy time for producers, balancing fieldwork and calving season. Unfortunately, some tasks may slip through the ...

Following the confirmation of 11 measles cases, 7 in Buenos Aires City and 4 in Buenos Aires province, Argentina's Health ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.